Ferritin, another target of IRP1 and IRP2, binds free cellular iron and prevents ferroptosis (LaVaute et al., 2001)
Nutrients (2020) 12(1):222
Clinical trials show that approximately 8 to 12 percent of patients discontinue GLP-1 therapy specifically due to side effectsthe vast majority experience acceptable symptoms within the first month
The concept of 'stacking' combining multiple pharmacological agents to achieve enhanced body composition outcomes is largely driven by online forums, social media communities, and unregulated wellness markets rather than clinical science
VK2735 is another medication that mimics both GLP-1 and GIP, like tirzepatide
While GLP-1RAs offer substantial benefits, their psychological impact requires further investigation to ensure long-term safety